Adherence to therapies in patients with type 2 diabetes

LE García-Pérez, M Álvarez, T Dilla, V Gil-Guillén… - Diabetes Therapy, 2013 - Springer
Adherence to therapy is defined as the extent to which a person's behavior in taking
medication, following a diet, and/or executing lifestyle changes, corresponds with agreed …

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

T Vilsbøll, M Christensen, AE Junker, FK Knop… - Bmj, 2012 - bmj.com
Objective To determine whether treatment with agonists of glucagon-like peptide-1 receptor
(GLP-1R) result in weight loss in overweight or obese patients with or without type 2 …

The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010

S Stark Casagrande, JE Fradkin, SH Saydah… - Diabetes …, 2013 - Am Diabetes Assoc
OBJECTIVE To determine the prevalence of people with diabetes who meet hemoglobin
A1c (A1C), blood pressure (BP), and LDL cholesterol (ABC) recommendations and their …

Standards of medical care in diabetes—2011

American Diabetes Association - Diabetes care, 2011 - Am Diabetes Assoc
A. Children and adolescents 1. Type 1 diabetes Glycemic control a. Screening and
management of chronic complications in children and adolescents with type 1 diabetes i …

Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP)

RM Bergenstal, AJ Ahmann, T Bailey, RW Beck… - 2013 - liebertpub.com
Underutilization of glucose data and lack of easy and standardized glucose data collection,
analysis, visualization, and guided clinical decision making are key contributors to poor …

EADSG guidelines: insulin therapy in diabetes

B Silver, K Ramaiya, SB Andrew, O Fredrick, S Bajaj… - Diabetes therapy, 2018 - Springer
Executive Summary and Recommendations A diagnosis of diabetes or hyperglycemia
should be confirmed prior to ordering, dispensing, or administering insulin (A). Insulin is the …

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

J Rosenstock, N Aggarwal, D Polidori, Y Zhao… - Diabetes …, 2012 - Am Diabetes Assoc
OBJECTIVE To evaluate the effects of canagliflozin, a sodium-glucose cotransporter 2
inhibitor, in type 2 diabetes mellitus inadequately controlled with metformin monotherapy …

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a …

RM Bergenstal, C Wysham, L MacConell, J Malloy… - The Lancet, 2010 - thelancet.com
Background Most patients with type 2 diabetes begin pharmacotherapy with metformin, but
eventually need additional treatment. We assessed the safety and efficacy of once weekly …

Estimating a reasonable patient panel size for primary care physicians with team-based task delegation

J Altschuler, D Margolius… - The Annals of Family …, 2012 - Annals Family Med
PURPOSE Primary care faces the dilemma of excessive patient panel sizes in an
environment of a primary care physician shortage. We aimed to estimate primary care panel …

Preservation of β-cell function: the key to diabetes prevention

RA DeFronzo, MA Abdul-Ghani - The Journal of Clinical …, 2011 - academic.oup.com
Abstract Context: The Centers for Disease Control and Prevention estimates that there are
approximately 79,000,000 individuals in the United States with prediabetes [impaired …